These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 2013938)

  • 1. Making bone marrow transplants more safe.
    Skolnick A
    JAMA; 1991 May; 265(17):2171. PubMed ID: 2013938
    [No Abstract]   [Full Text] [Related]  

  • 2. Influence of various conditioning regimens on the outcome of bone marrow transplantation for leukemia.
    Devergie A; Socie G; Esperou-Bourdeau H; Ribaud P; Traineau R; Gluckman E
    Nouv Rev Fr Hematol (1978); 1991; 33(6):437-9. PubMed ID: 1818295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F; Copelan E; Crilley P; Bolwell B; Avalos B; Klein J; Territo M; Gajewski J
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Busulfan/cyclophosphamide plus bone marrow transplantation is not sufficient to eradicate the malignant clone in juvenile chronic myelogenous leukemia.
    Urban C; Schwinger W; Slavc I; Schmid C; Gamillscheg A; Lackner H; Hauer C; Pakisch B
    Bone Marrow Transplant; 1990 May; 5(5):353-6. PubMed ID: 2190661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of busulfan containing chemotherapy for conditioning patients with leukemia for bone marrow allografting.
    Tutschka PJ
    Bone Marrow Transplant; 1993; 12 Suppl 1():34-6. PubMed ID: 8374557
    [No Abstract]   [Full Text] [Related]  

  • 6. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide.
    Santos GW; Tutschka PJ; Brookmeyer R; Saral R; Beschorner WE; Bias WB; Braine HG; Burns WH; Elfenbein GJ; Kaizer H
    N Engl J Med; 1983 Dec; 309(22):1347-53. PubMed ID: 6355849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of total body irradiation as based on the comparison of preparation regimens for allogeneic bone marrow transplantation for acute leukemia in first complete remission.
    Inoue T; Ikeda H; Yamazaki H; Tang JT; Song C; Teshima T; Murayama S; Ohtani M; Shibata H; Masaoka T
    Strahlenther Onkol; 1993 Apr; 169(4):250-5. PubMed ID: 8488461
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Total body irradiation in hematology: clinical indications and prospects].
    Corvò R
    Recenti Prog Med; 1999 Nov; 90(11):601-4. PubMed ID: 10608150
    [No Abstract]   [Full Text] [Related]  

  • 9. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation.
    Spitzer TR; Cottler-Fox M; Torrisi J; Cahill R; Greenspan A; Lynch M; Deeg HJ
    Bone Marrow Transplant; 1989 Sep; 4(5):559-65. PubMed ID: 2676044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autologous bone marrow transplantation in patients with acute nonlymphocytic leukemia, using ex vivo marrow treatment with 4-hydroperoxycyclophosphamide.
    Yeager AM; Kaizer H; Santos GW; Saral R; Colvin OM; Stuart RK; Braine HG; Burke PJ; Ambinder RF; Burns WH
    N Engl J Med; 1986 Jul; 315(3):141-7. PubMed ID: 3523241
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Morbidity and non-relapse mortality after allogeneic bone marrow transplantation in adult leukemia patients conditioned with busulfan plus cyclophosphamide: a retrospective comparison of oral versus intravenous busulfan.
    Kim SE; Lee JH; Choi SJ; Lee JH; Ryu SG; Lee KH
    Haematologica; 2005 Feb; 90(2):285-6. PubMed ID: 15710597
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of preparative regimens in transplants for children with acute lymphoblastic leukemia.
    Davies SM; Ramsay NK; Klein JP; Weisdorf DJ; Bolwell B; Cahn JY; Camitta BM; Gale RP; Giralt S; Heilmann C; Henslee-Downey PJ; Herzig RH; Hutchinson R; Keating A; Lazarus HM; Milone GA; Neudorf S; Perez WS; Powles RL; Prentice HG; Schiller G; Socié G; Vowels M; Wiley J; Yeager A; Horowitz MM
    J Clin Oncol; 2000 Jan; 18(2):340-7. PubMed ID: 10637248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic and syngeneic marrow transplantation following high dose dimethylbusulfan, cyclophosphamide and total body irradiation.
    Kanfer EJ; Buckner CD; Fefer A; Storb R; Appelbaum FR; Hill RS; Amos D; Doney KC; Clift RA; Shulman HM
    Bone Marrow Transplant; 1987 Apr; 1(4):339-46. PubMed ID: 3332142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial comparing busulfan vs total body irradiation in allogeneic marrow transplant recipients with hematological malignancies.
    Ringdén O; Ruutu T; Remberger M; Nikoskelainen J; Volin L; Vindeløv L; Parkkali T; Lenhoff S; Sallerfors B; Ljungman P
    Transplant Proc; 1994 Jun; 26(3):1831-2. PubMed ID: 8030160
    [No Abstract]   [Full Text] [Related]  

  • 15. Allogeneic bone marrow transplantation for children with acute leukemia: cytoreduction with fractionated total body irradiation, high-dose etoposide and cyclophosphamide.
    Duerst RE; Horan JT; Liesveld JL; Abboud CN; Zwetsch LM; Senf ES; Constine LS; Raubertas RF; Passarell JA; DiPersio JF
    Bone Marrow Transplant; 2000 Mar; 25(5):489-94. PubMed ID: 10713624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Busulfan, cyclophosphamide and fractionated total body irradiation as a preparatory regimen for marrow transplantation in patients with advanced hematological malignancies: a phase I study.
    Petersen FB; Buckner CD; Appelbaum FR; Clift RA; Sanders JE; Bensinger WI; Storb R; Witherspoon RP; Sullivan KM; Bearman SI
    Bone Marrow Transplant; 1989 Nov; 4(6):617-23. PubMed ID: 2684307
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy versus allogeneic bone marrow transplantation in adults with acute lymphoblastic leukemia.
    Mrsić M; Nemet D; Labar B; Bogdanić V; Radman I; Zupancić-Salek S; Kovacević-Metelko J; Aurer I; Maravić N
    Transplant Proc; 1993 Feb; 25(1 Pt 2):1268-70. PubMed ID: 8442109
    [No Abstract]   [Full Text] [Related]  

  • 18. Can total body irradiation be supplanted by busulfan in cytoreductive regimens for bone marrow transplantation?
    Shank B
    Int J Radiat Oncol Biol Phys; 1995 Jan; 31(1):195-6; discussion 202-3. PubMed ID: 7995753
    [No Abstract]   [Full Text] [Related]  

  • 19. Can busulfan replace fractionated total body irradiation as conditioning regimen for allogeneic bone marrow transplantation in children with acute lymphoblastic leukemia.
    Wachowiak J; Bettoni C; Lange A; Malicki J; Kaczmarek-Kanold M; Głuszak B; Suchnicki K; Daszkiewicz P; Ebell W
    Acta Haematol Pol; 1995; 26(4):377-84. PubMed ID: 8571739
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide is feasible in bone marrow transplantation for osteopetrosis.
    Naithani R
    Pediatr Transplant; 2015 Nov; 19(7):801-2. PubMed ID: 26179773
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.